As Gilead (GILD +0.6%) awaits FDA approval of its Quad on August 27, Deutsche says U.S. HIV...

|About: Gilead Sciences, Inc. (GILD)|By:, SA News Editor

As Gilead (GILD +0.6%) awaits FDA approval of its Quad on August 27, Deutsche says U.S. HIV treatment guidelines are already adding the drug. The firm thinks consensus expectations are undervaluing its potential, and its launch will surprise to the upside. The firm raises its price target to $68 from $65 and reiterates its Buy rating on the stock.